Follow-The-Filings

Security · featured owners

BMRN Biomarin Pharmaceutical Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 5 Owners
  • Max 11.4%
  • $1.4B
  • 2 add 2 reduce

BMRN (Biomarin Pharmaceutical Inc.) is held in 5 featured 13F books as of 2026 Q2. Michael Krensavage - Krensavage Asset Management is the largest tracked holder by portfolio weight (11.4%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 11.4% (Michael Krensavage - Krensavage Asset Management) · not free-float ownership

  1. Michael Krensavage 11.4%
  2. Palo Alto Investors reduce 5.4%
  3. Andreas Halvorsen add 1.2%
  4. Torray Investment Partners reduce 0.60%
  5. Dodge & Cox add 0.44%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Dodge & Cox 2026 Q2 0.44% Add +1.9% 14,844,930 $849M history
Andreas Halvorsen - Viking Global Investors 2026 Q2 1.2% Add +7.9% 7,616,563 $436M history
Palo Alto Investors 2026 Q2 5.4% Reduce −0.4% 682,777 $39M history
Michael Krensavage - Krensavage Asset Management 2026 Q2 11.4% Hold 524,786 $30M history
Torray Investment Partners 2026 Q2 0.60% Reduce −0.6% 77,705 $4M history

5 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 14 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 5.02 Filing Doc
8-K 8.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K/A 8.01,9.01 Filing Doc
8-K 5.02,5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 1.01,2.01,2.03,7.01,9.01 Filing Doc
8-K 8.01 Filing Doc
DEFA14A Filing Doc
8-K 8.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 13 rows shown

Filed Form Detail Links
4 Period Sep 10, 2026 Filing Doc
4 Period Sep 2, 2026 Filing Doc
4 Period Jun 2, 2026 · 9 forms Filing Doc
4 Period May 20, 2026 Filing Doc
4 Period May 7, 2026 Filing Doc
4 Period Mar 17, 2026 · 3 forms Filing Doc
4 Period Mar 18, 2026 Filing Doc
4 Period Mar 16, 2026 · 2 forms Filing Doc
4 Period Mar 13, 2026 · 2 forms Filing Doc
4 Period Mar 16, 2026 Filing Doc
4 Period Mar 13, 2026 Filing Doc
4 Period Mar 11, 2026 Filing Doc
4 Period Feb 26, 2026 Filing Doc

Updated about 11 hours ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.42B $2.85B $3.22B
Gross profit * $1.9B $2.27B $2.5B
Gross margin * 78.7% 79.7% 77.7%
Net income $167.64M $426.86M $348.9M
Net margin * 6.9% 15.0% 10.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $2.96B $3.23B $3.95B
Total non-current assets * $3.89B $3.76B $3.64B
Total assets $6.84B $6.99B $7.59B
Total current liabilities $1.18B $0.607B $0.759B
Total non-current liabilities * $713.03M $723.96M $747.99M
Total equity $4.95B $5.66B $6.09B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $159.26M $572.84M $827.99M
Cash from investing -$111.24M $136.49M -$414.24M
Cash from financing -$18.73M -$526.45M -$42.39M
Net change in cash $30.6M $187.72M $368.84M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders